Praluent 75 mg/mL is a formulation of alirocumab, a PCSK9 inhibitor used to lower low-density lipoprotein (LDL) cholesterol levels [1]. It is administered via subcutaneous injection [2]. The typical starting dose for Praluent is 75 mg every two weeks [3]. In some cases, doses can be increased to 150 mg every two weeks or 75 mg weekly if LDL cholesterol goals are not met [3].
What is Praluent used for?
Praluent is prescribed to adults with very high LDL cholesterol due to conditions such as heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH), or those with established cardiovascular disease who need additional LDL-C lowering [3]. It is used in conjunction with diet and maximally tolerated statin therapy [3].
How does Praluent work?
Alirocumab targets and inhibits the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein [1]. PCSK9 normally degrades LDL receptors on the surface of liver cells. By inhibiting PCSK9, alirocumab increases the number of LDL receptors available to clear LDL cholesterol from the bloodstream, thereby reducing LDL-C levels [1].
When does Praluent's patent expire?
Patent protection for Praluent is complex and involves multiple patents. According to DrugPatentWatch.com, the earliest expected patent expiration for alirocumab is in 2027, with subsequent patents extending further [4]. However, patent expiry dates can be subject to legal challenges and variations in different regions [4].
Can biosimilars be developed for Praluent?
Yes, biosimilars for Praluent can be developed once key patents expire [4]. The development and approval process for biosimilars are regulated by health authorities and require demonstrating high similarity to the reference product in terms of quality, safety, and efficacy [5]. The availability of biosimilars can potentially increase competition and reduce costs.
What are the side effects of Praluent?
Common side effects reported with Praluent include nasopharyngitis (common cold), influenza, and injection site reactions such as redness, bruising, or pain [2]. Serious allergic reactions are rare but possible [2]. Patients should discuss any concerns with their healthcare provider.
How does Praluent compare to other PCSK9 inhibitors?
Praluent (alirocumab) and Repatha (evolocumab) are both PCSK9 inhibitors with similar mechanisms of action and indications for lowering LDL cholesterol [6]. They are often compared in terms of efficacy, dosing regimens, and side effect profiles [6]. Clinical studies have shown both drugs to be effective in reducing LDL cholesterol [6].
What is the cost of Praluent?
The cost of Praluent can vary depending on insurance coverage, pharmacy, and geographic location. It is typically administered as a prescription medication, and patients may have access to savings programs offered by the manufacturer [7]. The list price of Praluent is publicly available but out-of-pocket costs can differ significantly for individuals.